Business Context and Reporting Period
Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 08, 2021
Reporting Period: Event-based report for October 08, 2021
Business Context: The Company is an emerging growth company focused on developing novel therapies. This filing reports the presentation of clinical data for its investigational drug CTX-009 (ABL001/ES104) at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Key Financial Metrics
This Form 8-K is an event-driven filing and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the dissemination of clinical data regarding CTX-009. No financial or operational changes compared to a prior period are detailed in this specific document.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the clinical data presentation but does not include specific management commentary, future guidance, or risk factors within the body of this 8-K text.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific clinical trial results and data regarding CTX-009.
- Verify the Company's current cash position and runway by consulting the most recent 10-Q or 10-K filing, as this 8-K contains no financial data.
- Monitor subsequent regulatory filings for updates on the development timeline of CTX-009 following the conference presentation.